FROM REUTERS: The U.S. Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs.
The prices go into effect in 2027, including a monthly price of $274 for Novo Nordisk’s (NOVOb.CO), opens new tab popular GLP-1 drug semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes.
AstraZeneca’s leukemia drug Calquence, Boehringer’s lung treatment Ofev and Pfizer’s breast cancer drug Ibrance took the biggest hits from this round of Medicare negotiations, each slashed by over $4,000 from estimated net prices.
Medicare reports that savings on the 15 drugs ranged from 38% to 85%.
Additional drugs included GSK’s asthma and COPD inhaler Trelegy Ellipta, which will cost $175, down from its list price of $654, and AbbVie’s irritable bowel syndrome medicine Linzess, going from $539 to $136.
🚨 𝐌𝐞𝐝𝐢𝐜𝐚𝐫𝐞 𝐒𝐥𝐚𝐬𝐡𝐞𝐬 𝐏𝐫𝐢𝐜𝐞𝐬 𝐟𝐨𝐫 𝟏𝟓 𝐏𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬
The latest price cuts amount to $12 billion in savings, according to the Centers for Medicare & Medicaid Services.
Read here:https://t.co/7qgpsVpihO pic.twitter.com/uQZ6YyTn9V
— The Epoch Times (@EpochTimes) November 26, 2025
The US Medicare health plan said that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs https://t.co/3ii7Yal27T
— Reuters (@Reuters) November 26, 2025
READ MORE AT REUTERS
The Dennis Michael Lynch Podcast archive is available below, with the most recent on top. Never miss an episode. Subscribe to the show by downloading The DML News App or go to Apple Podcasts.
